TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 16 and ≤ 70~* Signed informed consent~* Adequate vital organ function~* No active infection, or asymptomatic infection well controlled by antibiotic HIV negative by ELISA or RT-PCR \[if ELISA is positive and RT-PCR is negative, the ELISA is considered false positive\]~* Hepatitis B and C negative by serology or RT-PCR~* Performance status: Karnofsky Performance Status Score ≥ 60%.~Exclusion Criteria:~* Those with any Sorror's co-morbidity factors with score \> 3~* 2 or more Sorror's factors with composite score of ≥ 3

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus / Rapamycin (TAC/RAPA) (Type: ACTIVE_COMPARATOR): Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Rapamycin: given the day before transplant and continued daily for at least one year.
- Tacrolimus / Methotrexate (TAC/MTX) (Type: ACTIVE_COMPARATOR): Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Methotrexate: given on days 1, 3, 6 and 11, after transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least primarily educated.~* Accord with Probable Alzheimer disease of National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association(NINCDS-ADRDA)'s Criteria.~* 10 points ≤ Minimum Mean-Square Error(MMSE) ≤ 24 points.~* Hachinski ischemia scale \<4 points.~* Hamilton depression scale ≤10 points.~* Should have stable accompanying person, or at least contact 2 hours per day, 4 days per week with accompanying person. The accompanying person should help the patient throughout the trial.~* Signed the information consent form.~Exclusion Criteria:~* Have been in other clinical trials within 30 days before this trial' start.~* women during pregnancy or lactation.~* Dementia caused by other diseases.~* previous nervous system diseases.~* Abnormal laboratory results.~* Uncontrolled hypertension.~* Unstable or serious diseases of heart, lung, liver, kidney and blood.~* Visual or auditory handicap.~* Significant focal lesions revealed by electronic computer X-ray tomography(CT) or magnetic resonance imaging(MRI) in one year before enrollment.~* Alcohol abuse or drug abuse.~* psychotic, including patients with serious depression.~* Patients being in drug therapy of Alzheimer disease which cannot be stopped.~* In treatment of heparin, Polysaccharide sulfate, mannose ester 3 weeks before the recruitment.~* Investigator consider the patient cannot finish this trial for any reason.~* Relatives or employees of the investigators, staff of the investigate centers, contract research organization and sponsor.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- sodium oligo-mannurarate 900mg (Type: EXPERIMENTAL): None
- sodium oligo-mannurarate 600mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have given written informed consent to participate in this study in accordance with local regulations~2. Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype)~3. Be aged \> 6 years old~4. Have FEV1 \>40 % and \< 90% predicted~5. Be able to perform all the techniques necessary to measure lung function~Exclusion Criteria:~1. Investigators, site personnel directly affiliated with this study, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.~2. Be considered terminally ill or eligible for lung transplantation~3. Have had a lung transplant~4. Be using nebulized hypertonic saline in the 4 weeks prior to visit 1~5. Have had a significant episode of hemoptysis (\>60 mL) in the three months prior to enrolment~6. Have had a myocardial infarction in the three months prior to enrolment~7. Have had a cerebral vascular accident in the three months prior to enrolment~8. Have had major ocular surgery in the three months prior to enrolment~9. Have had major abdominal, chest or brain surgery in the three months prior to enrolment~10. Have a known cerebral, aortic or abdominal aneurysm~11. Be breast feeding or pregnant, or plan to become pregnant while in the study~12. Be using an unreliable form of contraception (female subjects at risk of pregnancy only)~13. Be participating in another investigative drug study, parallel to, or within 4 weeks of visit 0~14. Have a known allergy to mannitol~15. Be using beta blockers~16. Have uncontrolled hypertension - systolic BP \> 190 and / or diastolic BP \> 100~17. Have a condition or be in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient's participation in the study~18. Be 'Mannitol Tolerance Test positive'~    -

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): active treatment
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Volunteer~* Willing and able to give informed consent~* Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic~* Male and female subjects aged 18 to 55 years (inclusive)~* Subjects must agree to use an adequate method of contraception from admission through 12 weeks after last administration~Exclusion Criteria:~* Evidence or history of clinically significant abnormalities or disease or chronic respiratory disorders~* Any presence or history of a clinically significant allergy including any adverse reaction to study drug~* History of drug or alcohol abuse within the past 2 years~* Smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked)~* Donation or loss of greater than 400 mL of blood within the previous 3 months~* Have received any prescription medication within 4 weeks or investigational medication within 12 weeks of study (exception: contraceptives are permitted)~* Have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days)~* Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months~* If female, nursing, lactating or pregnant~* Regular alcohol consumption in males \>21 units per week and females \>14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)~* Surgery scheduled during the study or within 3 weeks after last dose~* History of familial long QT syndrome or history of sudden death in family members aged \< 30 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- test product A (Type: EXPERIMENTAL): salmeterol and fluticasone propionate, 2 puffs
- reference product D (Type: ACTIVE_COMPARATOR): salmeterol and fluticasone propionate, 2 puffs
- test product B (Type: EXPERIMENTAL): salmeterol and fluticasone propionate, 6 puffs
- reference product E (Type: ACTIVE_COMPARATOR): salmeterol and fluticasone propionate, 6 puffs
- test product C (Type: EXPERIMENTAL): salmeterol and fluticasone propionate, 12 puffs
- reference product F (Type: ACTIVE_COMPARATOR): salmeterol and fluticasone propionate, 12 puffs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Probiotics for Constipation in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 to 80 years old~* Provision of written informed consent~* Diagnosis of PD made by a Neurologist using UK Brain Bank Criteria~* Fulfils criteria for functional constipation according to the Rome IV Criteria during in the preceding 6 months with frequency of bowel movements less than 3 times per week~Exclusion Criteria:~* Ingestion of probiotics in the preceding 4 weeks~* Use of antibiotics in the preceding 4 weeks~* History of gastrointestinal disorders or surgery~* Known or suspected allergy to probiotics~* Comorbidities that prevent reliable completion of study assessments~* Prior functional neurosurgery for PD or treatment with apomorphine infusion~* Recent initiation of dopaminergic medications in the preceding 3 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Probiotics capsules
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules containing maltodextrin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Patients must be receiving hemodialysis; \* Have elevated parathyroid hormone levels; \* Not be pregnant or nursing; and \* Not have had a heart attack in the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG 073 (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Pain Control After Elective Caesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with an American Society of Anaesthesiologists physical status of I to III scheduled for elective caesarean section in spinal anaesthesia~* Surgery time does not exceed 60 minutes~* Patients without previous opioid and psychotropic medication~* Patients ranged 19-45 years old~* Patients who have given written informed consent~Exclusion Criteria:~* Recidivist alcoholics~* Local skin infection at the sites of acupuncture~* Age \< 19 and \> 45 years~* Switching to general anaesthesia in cases where spinal anaesthesia fails~* Surgery time more than 60 minutes~* Intraoperative complications (bleeding, required blood transfusion more than 6 units of packed cells, cardiovascular instability, required catecholamines except for short hypotension after induction of spinal anaesthesia )~* Patients who consumed opioid medication at least 6 months before surgery~* Patients who are unable to understand the consent form and fill in the study questionnaire~* History of psychiatric disease

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Verum acupuncture (Type: EXPERIMENTAL): Each patient will receive 16 permanent indwelling acupuncture needles, embedded in adhesive tape, bilaterally in addition to standard postoperative analgesia
- Placebo acupuncture (Type: PLACEBO_COMPARATOR): Each patient will receive 16 adhesive tapes mimicking the indwelling acupuncture needles bilaterally in addition to standard postoperative analgesia
- Standard therapy (Type: ACTIVE_COMPARATOR): Each patient will receive just standard postoperative analgesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has mild to moderate brown spots~* Has moderate to severe facial wrinkling~* Able to read, write, speak, and understand English~* In general good health~* If capable of having a child: must agree to practice a medically acceptable form of birth control.~* Intends to complete the study and willing to follow all study directions.~Exclusion Criteria:~* Allergies/sensitivity to skincare products or the test product ingredients~* Has a light or photosensitivity disorder or another medical condition that could increase risk to the subject or confuse the study results.~* Is taking medication that may cause skin sensitivity to light~* Has been using a product or medication that the study investigator determines will increase health risk to the subject or confuse the study results~* Has a facial skin condition (e.g. rosacea, acne, eczema, etc.) that could increase health risk to the subject or confuse the study results.~* Has skin cancer or a history of skin cancer.~* Has an immune deficiency disorder, active hepatitis, or an autoimmune disease.~* Has an uncontrolled metabolic condition (e.g. diabetes, hypertension)~* Is pregnant, nursing, or planning to become pregnant.~* Plans to start or change a hormone replacement therapy during the study.~* Has participated in another study in the past 30 days or plans to during the study.~* Is an employee or relative of the Study Site, Investigator, or Sponsor.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active Cell: Active Mask (Type: EXPERIMENTAL): Cleanser, Moisturizer, Active Mask
- Sham Cell: Sham Mask (Type: SHAM_COMPARATOR): Cleanser, Moisturizer, Sham Mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Effect of Distance Learning Vocational Rehabilitation on Employment Outcomes of Veterans With Psychiatric Illness and Histories of Legal Convictions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mental illness or substance use disorder~* history of a felony conviction or non-traffic related misdemeanor~Exclusion Criteria:~* cognitive impairment which prohibits active participation in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Self-help resources (Type: ACTIVE_COMPARATOR): a self-help vocational manual
- Compass (Type: EXPERIMENTAL): a distant learning vocational program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron-Deficiency Anemia in Infants in Two Weekly Programs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages ranging between six and 24 months old~Exclusion Criteria:~* Positive results for the Guthrie test~* Use of ferrous sulfate supplements~* Infections process at the time of first consultation

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): For infants with ages between six and 24 months, iron supplementation is the main treatment for iron deficiency.This study was carried out using two intervention groups. All children received 12 weekly doses of 25 mg of elemental iron.~Group 1 administered in the government healthcare clinic. Group 2 administered children's home.~The study showed treatment compliance in both groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of StentOptimizer With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Percutaneous coronary intervention indicated clinically.~2. IVUS used as part of the standard procedure.~3. Subject must be \>=40 yrs.~4. Subject must provide written informed consent.~Exclusion Criteria:~1. Low image quality as determined by the investigator.~2. Subject is pregnant or nursing.~3. Acute ST segment elevation myocardial infarction (STEMI) that has not been stabilized.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stent deployment evaluation (Type: None): The study group consisted of patients that underwent IVUS guided stent implantation. Stent deployment evaluation was done with the experimental StentOptimizer as well as IVUS and QCA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lifestyle Behavior Weight Loss Intervention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index of 25.0-39.9 kg/m2 (calculated using height and weight)~* Current enrollment in government assistant programs (for example, WIC, food stamp (SNAP), or Madicaid)~* 6 weeks - 3.5 years postpartum~* 18-45 years old~* Fluency in speaking, reading, and writing English~* Ownership of a smart phone with unlimited text messages and internet access~* Committed to a three-week intervention study~Exclusion Criteria:~* Current pregnancy or lactation~* Plan to become pregnant during the trial~* Type 1 or 2 diabetes~* Untreated thyroid disease~* Drug or alcohol abuse or dependence within last six months~* Major psychiatric disorder (e.g., schizophrenia, bipolar)~* History of bulimia or anorexia~* Current taking of appetite suppressant or (antipsychotic) medications known to affect body weight~* Current participation in a weight control or drug study~* Current or planned participation in a commercial weight loss program~* Previous weight loss surgery~* Contraindications to physical activity

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): All participants will be assigned to the experimental group and receive a 3-weekly intervention via web and individual health coaching. The educational topics cover stress management, healthy eating, and physical activity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete